MetaCap

Kalaris Therapeutics (KLRS) vs Instil Bio (TIL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Instil Bio (TIL) has outperformed Kalaris Therapeutics (KLRS) over the past year, losing 60.2% versus a loss of 81.7%. Over five years, TIL leads with a -98.7% price change compared with -99.7% for KLRS. Instil Bio is the larger company by market cap ($35.5 million vs $30.5 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KLRS-81.74%TIL-60.20%
+64%-13%-89%
Nov 21, 20251 yearNov 20, 2026
KLRS-99.72%TIL-98.82%
+5%-50%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KLRS versus TIL key metrics
MetricKLRSTIL
Share price$1.28$5.23
Market cap$30.47M$35.47M
1-day change-5.19%-5.77%
YTD return-84.83%-52.45%
1-year return-81.74%-60.20%
5-year return-99.70%-98.72%
EPS (TTM)$-1.84$-3.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$10.77M
Revenue growth (YoY)—+152.38%
Net income (latest FY)$-43.44M$-71.37M
Operating margin—-745.39%
Net margin—-662.75%
52-week high$11.88$12.92
52-week low$1.25$5.14
Distance from 52-week high-89.23%-59.51%
Analyst consensusstrong_buynone
Avg. price target upside+1361.72%+33.84%
Average volume77.37K42.02K
Shares outstanding23.80M6.78M
Employees2017
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TIL has outperformed KLRS by 21.5 percentage points over the past year.

About Kalaris Therapeutics

KLRS stock →

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees

About Instil Bio

TIL stock →

Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees

KLRS vs TIL FAQ

Which is bigger, Kalaris Therapeutics or Instil Bio?

Instil Bio (TIL) is larger, with a market capitalization of $35.47M compared with $30.47M for Kalaris Therapeutics (KLRS).

Which stock has performed better over the past year, KLRS or TIL?

TIL returned -60.20% over the past 12 months, compared with -81.74% for KLRS (price return, excluding dividends). Past performance does not predict future results.

Are Kalaris Therapeutics and Instil Bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons